BioSpace News Archive

uLab Systems™, the creator of the uSmile™ clear aligner system and the uDesign® treatment planning software, announces the upcoming release of uDesign 7.0, featuring AI-assisted Auto Staging and the uAssist digital assistant service.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare disorders, announced that the Universal Registration Document for the year ended December 31, 2021 has been filed with the French market authority.

Bio Products Laboratory, a leading manufacturer of plasma-derived protein therapies, based in Elstree, UK, announced it has received orphan drug marketing authorization for Coagadex® in Mexico.

Lyell Immunopharma, Inc. announced that members of its senior management team will participate in the BofA Securities 2022 Healthcare Conference on Wednesday, May 11 at 5:20 pm PT.

Global Blood Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022, and recent business progress.

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:20 p.m. EDT.

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, announced clinical development progress for CY6463, its lead program, and first quarter 2022 financial results.

Cytokinetics, Incorporated reported financial results for the first quarter of 2022.

Rezolute, Inc. announced that management will be hosting a corporate update call.

Cognition Therapeutics, Inc. announced that it will report financial results for the first quarter ended March 31, 2022 and provide a business update before the financial markets open on Tuesday, May 11, 2022.